论文部分内容阅读
分别采用酶联免疫吸附法（ＥＬＩＳＡ）及放射免疫法测定了１５９ 例子宫内膜异位症（内异症）患者（内异症组）血清子宫内膜抗体（ＥＭＡｂ）及卵巢上皮癌相关抗原（ＣＡ－１２５）水平，并与正常对照组比较。结果：治疗前内异症组ＥＭＡｂ 及ＣＡ－１２５ 阳性率均明显高于对照组，Ｐ均＜ ０．０５。单独测定ＥＭＡｂ诊断内异症的敏感性为６４．１５％ ，特异性为９２．５０％ ；单独测定ＣＡ－１２５ 的敏感性为８１．１３％ ，特异性为９７．５０％ 。如以ＥＭＡｂ 及ＣＡ－１２５ 均阳性为诊断标准，则诊断内异症的敏感性为５４．００％ ，特异性为１００％ 。治疗后１、３ 个月复查，ＥＭＡｂ 及ＣＡ－１２５ 阳性率均明显降低。认为测定血清ＥＭＡｂ、ＣＡ－１２５ 是目前较好的无创伤性诊断内异症的辅助方法，亦有助于内异症的疗效判定，联合测定ＥＭＡｂ 及ＣＡ－１２５，则更能提高诊断价值。
Serum endometrial antibody (EMAb) and epithelial ovarian cancer-associated antigen (EMAb) were detected in 159 patients with endometriosis (endometriosis) (endometriosis group) by enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (CA-125) levels, and compared with the normal control group. Results: The positive rates of EMAb and CA-125 in the endometriosis group before treatment were significantly higher than those in the control group (all P <0.05). The sensitivity and specificity of EMAb in the diagnosis of endometriosis were 64.15% and 92.50%, respectively. The sensitivity and specificity of CA-125 alone were 81.13% and 97.50% respectively. If both EMAb and CA-125 positive diagnostic criteria, the diagnosis of endometriosis sensitivity was 54.00%, specificity of 100%. One and three months after treatment, the positive rates of EMAb and CA-125 were significantly decreased. It is considered that the determination of serum EMAb and CA-125 is a good noninvasive adjuvant method for noninvasive diagnosis of endometriosis. It is also helpful to determine the efficacy of endometriosis. Combined determination of EMAb and CA-125 can improve the diagnostic value.